CNB Bank’s VYNE Therapeutics VYNE Stock Holding History

CNB Bank’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-14	Closed	-$2K	–	451
2020 Q3	$2K	Hold	14	–	–	﹤0.01%	364
2020 Q2	$2K	Buy	+14	New	+$1.9K	﹤0.01%	393

Other funds holding VYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

CNB Bank's VYNE Position: Q4 2020 in Review

CNB Bank sold out of VYNE Therapeutics (VYNE) in Q4 2020, closing a stake of 14 shares — an estimated $2K sold.

CNB Bank first reported a position in VYNE in Q2 2020 and held it in 2 quarters. The position peaked at $2K in Q3 2020. 104 funds tracked by Wall St. Rank hold VYNE as of Q4 2020.

CNB Bank reported no remaining VYNE Therapeutics position as of Q4 2020 after selling out during the quarter.
CNB Bank sold 14 VYNE Therapeutics shares in Q4 2020, an estimated $2K.
CNB Bank first reported a position in VYNE Therapeutics in Q2 2020 and held it in 2 quarters.
CNB Bank's VYNE Therapeutics position peaked at $2K in Q3 2020.
104 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2020.

Based on CNB Bank's 13F filing for Q4 2020, filed 27 Jan 2021.